In this video, Michael Staehler, MD, a professor of Urology at the University of Munich, discusses early results with 68GA-EMP-100 PET, a novel agent for imaging c-MET expression in renal cell carcinoma. Staehler presented that abstract, “First in-human results of 68GA-EMP-100 PET for imaging c-MET expression in renal cell carcinoma,” at the 2022 AUA annual meeting (abstract PD18-11).
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Studies show low urinary bladder interference on flotufolastat F 18 scans
June 11th 2024“The ability to gather actionable information from PSMA PET scans is important for physicians to make informed decisions about patient management for men with prostate cancer,” says Eugene Teoh, MBBS, MRCP, FRCR, DPhil.